Abstract 17009: Clinical Characteristics and In-hospital Outcomes of Cardiac Transplant Recipients With Allograft Vasculopathy Undergoing Percutaneous Coronary Intervention: Insights from the National Cardiovascular Data Registry
Introduction: Cardiac Allograft Vasculopathy (CAV) is a major limiting factor for long-term survival among cardiac transplant recipients. Large-scale data pertaining to the clinical characteristics and in-hospital outcomes in such patients undergoing Percutaneous Coronary Intervention (PCI) is lacking.
Methods: We analyzed 1,897,328 patients from the NCDR CathPCI registry™ who underwent PCI of at least 1 native vessel between July 2009-December 2013 from 1477 centers, of which 542 patients (0.03%) had previous cardiac transplantation. After 4:1 propensity matching, clinical characteristics and in-hospital outcomes were compared between 538 cardiac transplant recipients and 2128 non-transplant patients.
Results: Cardiac transplant recipients were more likely to have prior PCI, dyslipidemia, Canadian class 3/4 angina and were less likely to be smokers or present with ST segment-elevation myocardial infarction (0.9% vs. 7.1%, p<0.01) compared to the general population. Transplant recipients had fewer type C lesions (36% vs. 41% p=0.02) and were more likely to receive drug-eluting stents (DES: 81% vs. 76% p<0.01). In-hospital mortality, composite of death/MI/stroke, and bleeding complications were not significantly different between propensity-matched groups. (Table)
Conclusions: Our large database analysis demonstrate that despite some differences in clinical characteristics, in-hospital outcomes among cardiac transplant recipients undergoing PCI for focal lesions associated with CAV were similar to the general population. Use of DES was higher in this group.
Author Disclosures: S.R. Krim: None. M. Alkhouli: None. T.W. Dasari: None. G.C. Fonarow: None. J.F. Saucedo: None. R. Alvarez: None. H. Ibrahim: None. D. Dai: None. M. Costa: None. T.Y. Wang: Research Grant; Modest; Lilly USA, Daiichi Sankyo, Gilead Science, GlaxoSmith Kline, American College of Cardiology, American Society of Nuclear Cardiology. Honoraria; Modest; Astra Zeneca, and the American College of Cardiology Foundation. J. Lindenfeld: None. J. Messenger: None.
- © 2014 by American Heart Association, Inc.